Northfield Files BLA For Blood Substitute, Seeks Capital Infusion
Northfield Laboratories hopes to translate enthusiasm on Wall Street for the first BLA submission for a blood substitute into at least $40 mil. of additional capital to help commercialize PolyHeme.
You may also be interested in...
Northfield Laboratories hopes for action on its BLA for the human-derived hemoglobin substitute PolyHeme by February 2002.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials